semaglutide and heart problems Semaglutide: What impact does it really have on health? Popular GLP-1 weight-loss drugs like

However, already existing incontinence is not a contraindication for the surgery

The FDA said the supply pinch on the 0.25 and 0.5 formulations will continue through January 2023. Asked to what extent off-label use is aggravating this shortfall, Novo responded: While we recognize that some healthcare providers may be prescribing Ozempic for patients whose goal is to lose weight, it is up to the clinical discretion of each healthcare provider to choose the best treatment approach for their patients. The company continued: Novo Nordisk does not promote, suggest, or encourage off-label use of our medicines and is committed to fully complying with all applicable U.S

It is formulated with organic botanical extracts, clean preservatives, and zero harmful additives

This segment aired on March 3, 2026.